100 CAMBRIDGEPARK DRIVE, CAMBRIDGE, MA
Annual Report to Security Holders
Material Contracts, Unregistered Sales of Equity Securities, Reg. FD
Investor Presentation
Separation Agreement with Dr. Qing Zuraw; Chief Development Officer Departs
Announces $150 Million Private Placement
Stock Option Repricing Approved by Vor Biopharma Board on December 5, 2025
Vor Biopharma Inc. Announces $93.7 Million Equity Offering
Appoints Jeremy Sokolove, M.D. as Chief Medical Officer
Q1
FY 2025
Q3
Q2
FY 2024
Q2 amended
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(3)
Prospectus filed pursuant to Rule 424(b)(5)
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Amended Schedule 13D - Ownership Report